



COMPARISON OF SUBLINGUAL AND INTRAMUSCULAR ADMINISTRATION OF VITAMIN B12 FOR THE TREATMENT OF VITAMIN B12 DEFICIENCY IN CHILDREN

AYŞE TUĞBA-KARTAL^{1*} AND ZEYNEP ÇAĞLA-MUTLU²

¹Division of Pediatric Neurology, Faculty of Medicine, Ankara University, Ankara; ²Department of Pediatrics, Kütahya Parkhayat Hospital, Kütahya, Turkey

ABSTRACT

Background: In most countries, contrary to some disadvantages, such as pain, relatively higher cost, and poor adherence to treatment, intramuscular (IM) route is still the primary treatment method for Vitamin B12 (VB12) deficiency. In recent years, because of these difficulties, new treatment methods are being sought for VB12 deficiency. **Objectives:** We aimed to compare sublingual (SL) and IM routes of VB12 administration in children with VB12 deficiency and to compare the efficacy of methylcobalamin and cyanocobalamin therapy in these children. **Methods:** This retrospective study comprised 129 patients with VB12 deficiency (serum Vitamin 12 level \leq 200 pg/mL) aged 5–18 years. Based on the formulations of Vitamin 12, we divided the patients into three treatment groups as IM cyanocobalamin, SL cyanocobalamin, and SL methylcobalamin. **Results:** After Vitamin 12 therapy, serum Vitamin 12 levels increased significantly in all patients, and there was a statistically significant difference between the treatment groups ($p < 0.05$). **Conclusions:** SL cyanocobalamin and methylcobalamin were found as effective as IM cyanocobalamin for children with Vitamin 12 deficiency in correcting serum Vitamin 12 level and hematologic abnormalities. (REV INVEST CLIN. 2020;72(6):380-5)

Key words: Cyanocobalamin. Intramuscular. Methylcobalamin. Sublingual. Vitamin B12.

INTRODUCTION

The estimated prevalence of Vitamin B12 (VB12) deficiency in the general population varies between 1.5% and 15%^{1,2}. The most common cause of VB12 deficiency in children is inadequate dietary intake³. As VB12 cannot be produced by humans, it should be

obtained from animal-based foods, such as meat, milk, eggs, and fish^{4,5}. Therefore, vegetarianism and low socioeconomic conditions are important risk factors for VB12 deficiency⁶. Other causes are pernicious anemia, gastrectomy, bariatric surgery, gastritis, drugs (proton-pump inhibitors, H2 receptor blockers, antacids, etc.), and Imerslund-Gräsbeck syndrome^{7,8}.

***Corresponding author:**
Ayşe Tuğba Kartal
E-mail: dratugbakartal@gmail.com

Received for publication: 07-05-2020
Approved for publication: 29-06-2020
DOI: 10.24875/RIC.20000208

0034-8376 / © 2020 Revista de Investigación Clínica. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Intramuscular (IM) route is the primary choice of treatment for VB12 deficiency in most countries; however, it has some disadvantages, such as pain, high cost, and poor adherence to treatment^{9,10}. In recent years, because of these disadvantages, new methods are being sought for treating VB12 deficiency.

Dietary VB12 gets absorbed through two different pathways¹¹. Through the first pathway, VB12 binds intrinsic factor (IF), which is released by parietal cells in the stomach, following which the VB12-IF complex gets actively absorbed in the terminal ileum¹². Approximately 60% of the absorption of dietary VB12 occurs through this biochemical mechanism¹². Through the second pathway, dietary VB12 gets absorbed by simple diffusion (without binding to IF) along the entire intestine or it gets directly absorbed by sublingual (SL) capillaries¹³. Therefore, SL route for treating VB12 deficiency has several advantages, including potentially good adherence to treatment, safety, and low cost¹. In addition, this route enables the treatment of VB12 deficiency in patients with swallowing disorders or malabsorption syndrome (inflammatory intestinal diseases, intestinal surgery, short bowel syndrome, etc.)^{14,15}. In recent years, the importance of SL route has been recognized; however, few studies have evaluated this method, especially in children^{1,13,16}.

In the present study, we aimed to compare SL and IM routes of VB12 administration in children with VB12 deficiency and to compare the efficacy of methylcobalamin and cyanocobalamin therapy in these children.

METHODS

Study population

This retrospective study comprised 129 patients with VB12 deficiency (126 inadequate dietary intake and 3 pernicious anemia) aged 5-18 years, and conducted between January 2017 and December 2019. We obtained the data from the electronic medical record system and patient files at Parkhayat Hospital. Based on the formulations of VB12, we divided the patients into three treatment groups as IM cyanocobalamin, SL cyanocobalamin, and SL methylcobalamin. The study was approved by Kütahya University of Health

Sciences Ethics Committee and conducted in accordance with the ethical principles described by the Declaration of Helsinki (2020/05-12).

Inclusion criteria were as follows: (I) aged 5-18 years and (II) VB12 deficiency (serum VB12 level \leq 200 pg/mL). Exclusion criteria were as follows: (I) patients with chronic diseases that may affect hematologic parameters (sideroblastic anemia, thalassemia, aplastic anemia, etc.), (II) folate deficiency, (III) iron deficiency, (IV) renal disease, (V) using drugs that may affect the absorption of VB12 (metformin, proton pump inhibitors, phenobarbital, etc.), and (VI) having missing data.

Laboratory studies

Complete blood count was measured with automatic blood count device LH 750 (Beckman Coulter, Inc., USA), and VB12 level was measured with automatic biochemistry device Advia Centaur[®] XPT (Siemens, Berlin, Germany). The lower level of hemoglobin (Hb), white blood cell (WBC), and platelet was determined as follows: < 11 g/dL, < 4000 /mm³, and < 150.000 /mm³, respectively. VB12 level \leq 200 pg/mL was described as a deficiency. According to the protocol that is applied in our hospital, the treatment response of VB12 is reevaluated after 4 weeks in every patient.

Treatment protocols

IM route

A 1000 mcg every other day for 1 week, then weekly for 3 weeks (Dodex[®] ampule, 1000 mcg/1 ml cyanocobalamin).

SL route

A 1000 mcg once daily for 7 days, then every other day for 3 weeks (SL cyanocobalamin: Solgar[®] 1000 mcg SL tablet; SL methylcobalamin: Ocean Methyl B12 1000 mcg 10 mL spray).

Statistical analysis

The statistical analyses were performed using SPSS version 21 software. Continuous variables were calculated as mean \pm standard deviation (SD). A one-way

analysis of variance and Chi-square tests were used to assess comparisons between the treatment groups. *Post hoc* analysis was carried out by Tukey test. The independent t-test was used to compare pre-treatment and post-treatment values. $p < 0.05$ was considered as statistically significant.

RESULTS

A total number of 129 children with VB12 deficiency were included in this retrospective study (the treatment groups; IM cyanocobalamin group [n = 47], SL cyanocobalamin group [n = 43], and SL methylcobalamin group [n = 39]). Female/male ratio of IM cyanocobalamin, SL cyanocobalamin, and SL methylcobalamin groups was 21/26, 23/20, and 19/20, respectively ($p > 0.05$), and mean age of the groups was 12.7 ± 5.1 , 12.3 ± 2.1 , and 11.9 ± 5.6 years, respectively ($p > 0.05$). The demographic and laboratory characteristics of the study participants are summarized in Table 1.

After VB12 therapy, serum VB12 levels increased significantly in all patients, and there was a statistically significant difference between the treatment groups ($p < 0.05$). Mean pre-treatment VB12 levels of IM cyanocobalamin, SL cyanocobalamin, and SL methylcobalamin groups were found as 147.5 ± 37.7 , 137.2 ± 36.5 , and 146.7 ± 40.5 pg/mL, respectively ($p > 0.05$), and after the therapy, the levels were detected as 602.0 ± 156.1 , 483.4 ± 144.8 , and 565.5 ± 108.1 pg/mL, respectively ($p < 0.05$) (Table 1 and Fig. 1). In addition, mean \pm SD difference between serum VB12 levels before and after VB12 therapy of the treatment groups was found as 454.5 ± 118.4 , 346.2 ± 108.3 , and 418.8 ± 67.6 , respectively ($p < 0.05$) (Table 1).

Mean \pm SD difference between serum VB12 levels before and after VB12 therapy was found as in IM cyanocobalamin group versus SL cyanocobalamin group (454.5 ± 118.4 vs. 346.2 ± 108.3 , $p < 0.05$); in IM cyanocobalamin group versus SL methylcobalamin group (454.5 ± 118.4 vs. 418.8 ± 67.6 , $p < 0.05$); and in SL cyanocobalamin group versus SL methylcobalamin group (346.2 ± 108.3 vs. 418.8 ± 67.6 , $p < 0.05$) (Table 2).

Out of 129 patients, 76 (58.9%) were found to have anemia (Hb < 11 g/dL) before VB12 treatment. After

the 1st month of the treatment, the improvement ratios in anemia of the treatment groups (IM cyanocobalamin group, SL cyanocobalamin group, and SL methylcobalamin group) were detected as 13 (46.4%)/28, 7 (30.4%)/23, and 9 (36%)/25, respectively ($p > 0.05$). In addition, WBC and platelet counts did not change significantly either after VB12 therapy or between the treatment groups.

DISCUSSION

IM injection is a traditional choice of treatment for VB12 deficiency due to inadequate dietary intake, pernicious anemia, gastrectomy, ileal resection, or malabsorption syndrome^{17,18}. However, IM method is associated with some disadvantages, such as pain, high cost, poor adherence to treatment, and bleeding in patients with coagulation disorders¹⁹. Considering these issues, SL route is now being considered for VB12 administration. SL method enables direct absorption of VB12 under the tongue, bypassing intestinal absorption¹⁴. Moreover, this method has several advantages, for example, it is less costly, results in high patient satisfaction, does not require a hospital visit, is not painful, and does not result in injection-related injury¹⁶. However, few studies have evaluated the efficacy of SL administration of VB12 and compared it with that of IM administration.

Bensky et al. compared the efficacy of SL and IM administration of VB12 in terms of normalizing serum cyanocobalamin levels. In their study, 3451 patients received SL VB12 (1000 μ g/day for 6 months) and 830 patients received 1000 μ g/dose IM VB12 (every other day for 2 weeks, followed by once a week for 4 weeks). Pre-treatment mean values of serum cyanocobalamin level were increased from 298 ng/L to 551 ng/L in the SL group, whereas in the IM group, mean value increased from 234 pg/mL to 452 ng/L. The post-treatment values significantly differed between the two groups ($p < 0.001$). The authors concluded that SL route should be the first-line choice of treatment in patients with VB12 deficiency¹³. Sharabi et al. compared SL and oral routes in a randomized prospective study of 30 adults with VB12 deficiency. Participants were given one tablet daily of 500 μ g cyanocobalamin orally or sublingually or two tablets daily of a VB12 complex (250 μ g cobalamin, 100 mg thiamine, and 250 mg pyridoxine)

Table 1. The demographic and laboratory characteristics of the study participants

	IM cyanocobalamin group (n = 47)	SL cyanocobalamin group (n = 43)	SL methylcobalamin group (n = 39)	p
	Mean ± SD			
Age, year	12.7 ± 5.1	12.3 ± 2.1	11.9 ± 5.6	0.463
Gender, n	21/26	23/20	19/20	0.139
Female				
Male				
Serum vitamin B12, pg/mL				
Pre-treatment	147.5 ± 37.7	137.2 ± 36.5	146.7 ± 40.5	0.153
Post-treatment	602.0 ± 156.1	483.4 ± 144.8	565.5 ± 108.1	
p	< 0.001	< 0.001	< 0.001	–
ΔsVB12 levels before and after treatment	454.5 ± 118.4	346.2 ± 108.3	418.8 ± 67.6	< 0.001
Hb, gr/dl				
Pre-treatment	10.1 ± 1.3	10.4 ± 1.5	10.3 ± 1.6	0.154
Post-treatment	11.8 ± 1.2	11.3 ± 1.3	11.6 ± 1.4	0.142
p	< 0.001	< 0.001	< 0.001	–
MCV, fL				
Pre-treatment	82.6 ± 10.8	81.1 ± 6.8	82.3 ± 7.1	0.332
Post-treatment	78.7 ± 10.2	80.1 ± 6.8	79.3 ± 15.9	0.591
p	< 0.001	0.023	< 0.001	–
Anemia, n				
Pre-treatment	28 (59.5%)	23 (53.4%)	25 (64.1%)	0.417
Post-treatment	15 (31.9%)	16 (37.2%)	16 (41%)	0.351
WBC count, /mm³				
Pre-treatment	7266.6 ± 1556.5	8612.1 ± 1012.7	7877.5 ± 1890.2	0.211
Post-treatment	8924.4 ± 1015.4	8904.1 ± 2534.1	7351.2 ± 1199.9	0.124
p	0.131	0.342	0.457	–
Platelet count, /mm³				
Pre-treatment	290.833 ± 57.314	296.920 ± 95.949	291.374 ± 116.925	0.927
Post-treatment	272.142 ± 57.616	304.187 ± 89.928	299.333 ± 66.525	0.573
P	0.531	0.742	0.757	–

Hb: hemoglobin; IM: intramuscular; MCV: mean corpuscular volume; SL: sublingual; sVB12: serum Vitamin B12; WBC: white blood cell.

for 8 weeks. After 4 weeks, VB12 level normalized, and serum cyanocobalamin levels were increased from 108 to 286 pmol/L, 94 to 288 pmol/L, and 98 to 293 pmol/L, in SL, oral, and oral B-complex groups, respectively ($p = 0.0001$). The authors reported that

SL route is as effective as the oral route in treating VB12 deficiency²⁰. In a prospective open-labeled study, Delpre et al. tested 18 patients with VB12 deficiency. In their study, the patients received VB12 (2000 µg/day for 7-12 days) by SL route, and

Figure 1. Serum Vitamin B12 levels of the treatment groups.




Table 2. Tukey's *post hoc* analysis of the groups

	IM cyanoco- balamin group (n = 47)	SL cyanoco- balamin group (n = 43)	p	IM cyanoco- balamin group (n = 47)	SL methylco- balamin group (n = 39)	p	SL cyanoco- balamin group (n = 43)	SL methylco- balamin group (n = 39)	p
	Mean ± SD			Mean ± SD			Mean ± SD		
ΔsVB12 levels before and after treatment	454.5 ± 118.4	346.2 ± 108.3	< 0.001	454.5 ± 118.4	418.8 ± 67.6	0.032	346.2 ± 108.3	418.8 ± 67.6	<0.001

sVB12: serum Vitamin B12; IM: intramuscular; SL: sublingual.

serum VB12 level normalized rapidly and significantly in all the patients¹⁴.

To the best of our knowledge, this is the first study to compare two treatment methods (SL and IM) and two cobalamin types (cyanocobalamin and methylcobalamin) simultaneously in children with VB12 deficiency. Our results are consistent with those of previous studies. We found that SL cyanocobalamin and methylcobalamin were as effective as IM cyanocobalamin in treating VB12 deficiency in children. The serum VB12 level normalized in all the patients after 4 weeks. The mean VB12 level was found to be the highest in IM cyanocobalamin group and the lowest in SL cyanocobalamin group after the treatment.

Hematologic response time and degree to VB12 treatment vary according to the basal VB12 level of patients²¹. Anemia (Hb and mean corpuscular volume [MCV]) usually begins to improve in 1-2 weeks and normalizes within 6-8 weeks^{21,22}. Sezer et al. treated 135 children (aged between 1 month and 18 years) with VB12 deficiency. Treatment protocols were as follows: IM cyanocobalamin group “100 µg/day for 1 week, then 1000 µg on alternate days for a week, then 1000 µg 2 times a week for a week and finally once a week” and oral group “one B-complex tablet (50 mg thiamin, 250 mg pyridoxine, and 1000 µg cyanocobalamin) per day up to 1 month.” After the 1st month of treatment, Hb levels normalized and MCV decreased in 34% of patients in IM group and 19% of patients in the oral group²³. Verma et al. carried

out a prospective study in 28 children (aged between 6 months and 18 years) with macrocytic anemia, and oral methylcobalamin was given at a dosage of 30 µg/kg/day for 1 month. After the treatment, Hb levels normalized in 85.7% of the patients²⁴. In another study conducted by Andres et al., 30 patients were treated with oral VB12 (250-1000 µg/day) for >1 month. After the 1st month of treatment, anemia improved in only 54% of the patients²⁵.

Our results were in line with previous studies. After the 1st month of the treatment, the improvement in anemia was mostly detected in IM cyanocobalamin group (46.4%), whereas the least improvement was observed in SL cyanocobalamin group (30.4%). However, there was no statistical difference between the three groups. We thought that these differences between the studies were probably because of the case selection, follow-up time, treatment method, and drug selection.

The retrospective design is the most limiting factor of the study. Therefore, we did not investigate methylmalonic acid and homocysteine levels. In addition, short follow-up period and relatively small sample size are another limitations of the study.

In conclusion, SL cyanocobalamin and methylcobalamin are as effective as IM cyanocobalamin in correcting serum VB12 levels and hematologic abnormalities in children with VB12 deficiency. However, SL formulations, which are cheaper, safer, painless, and practical, have been less used than IM formulations for decades. Our results suggest that SL formulations can be used as the first-line treatment in children with VB12 deficiency.

REFERENCES

- Kotilea K, Quennery S, Decroës V, Hermans DA. Successful sublingual cobalamin treatment in a child with short-bowel syndrome. *J Pediatr Pharmacol Ther.* 2014;19:60-3.
- Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. *Am Fam Physician.* 2017;96:384-9.
- Balcı YI, Ergin A, Karabulut A, Polat A, Doğan M, Küçüktaşçı K. Serum Vitamin B12 and folate concentrations and the effect of the Mediterranean diet on vulnerable populations. *Pediatr Hematol Oncol.* 2014;31:62-7.
- Sezer RG, Bozaykut A, Akoğlu HA, Özdemir GN. The efficacy of oral Vitamin B12 replacement for nutritional Vitamin B12 deficiency. *J Pediatr Hematol Oncol.* 2018;40:e69-e72.
- van Walraven C, Austin P, Naylor CD. Vitamin B12 injections versus oral supplements. How much money could be saved by switching from injections to pills? *Can Fam Physician.* 2001; 47:79-86.
- Vidal-Alaball J, Butler CC, Cannings-John R, Goringe A, Hood K, McCaddon A, et al. Oral Vitamin B12 versus intramuscular Vitamin B12 for Vitamin B12 deficiency. *Cochrane Database Syst Rev.* 2005;20:CD004655.
- Green R. Vitamin B(12) deficiency from the perspective of a practicing hematologist. *Blood.* 2017;129:2603-11.
- Masucci L, Goeree R. Vitamin B12 intramuscular injections versus oral supplements: a budget impact analysis. *Ont Health Technol Assess Ser.* 2013;13:1-24.
- Gomollón F, Gargallo CJ, Muñoz JF, Vicente R, Lue A, Mir A, et al. Oral cyanocobalamin is effective in the treatment of Vitamin B12 deficiency in Crohn's disease. *Nutrients.* 2017;9:E308.
- Metaxas C, Mathis D, Jeger C, Hersberger KE, Arnet I, Walter P. Early biomarker response and patient preferences to oral and intramuscular Vitamin B12 substitution in primary care: a randomized parallel-group trial. *Swiss Med Wkly.* 2017;147:w14421.
- Butler CC, Vidal-Alaball J, Cannings-John R, McCaddon A, Hood K, Papaioannou A, et al. Oral Vitamin B12 versus intramuscular Vitamin B12 for Vitamin B12 deficiency: a systematic review of randomized controlled trials. *Fam Pract.* 2006;23:279-85.
- Bolaman Z, Kadikoylu G, Yukselen V, Yavasoglu I, Barutca S, Senturk T. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. *Clin Ther.* 2003;25:3124-34.
- Bensky MJ, Ayalon-Dangur I, Ayalon-Dangur R, Naamany E, Gafter-Gvili A, Koren G, et al. Comparison of sublingual vs. intramuscular administration of Vitamin B12 for the treatment of patients with Vitamin B12 deficiency. *Drug Deliv Transl Res.* 2019;9:625-30.
- Delpre G, Stark P, Niv Y. Sublingual therapy for cobalamin deficiency as an alternative to oral and parenteral cobalamin supplementation. *Lancet.* 1999;354:740-1.
- Thakkar K, Billa G. Treatment of Vitamin B12 deficiency-methylcobalamin? Cyanocobalamin? Hydroxocobalamin?-clearing the confusion. *Eur J Clin Nutr.* 2015;69:1-2.
- Parry-Strong A, Langdana F, Haeusler S, Weatherall M, Krebs J. Sublingual Vitamin B12 compared to intramuscular injection in patients with Type 2 diabetes treated with metformin: a randomized trial. *N Z Med J.* 2016;129:67-75.
- Castelli MC, Friedman K, Sherry J, Brazzillo K, Genoble L, Bhargava P, et al. Comparing the efficacy and tolerability of a new daily oral Vitamin B12 formulation and intermittent intramuscular Vitamin B12 in normalizing low cobalamin levels: a randomized, open-label, parallel-group study. *Clin Ther.* 2011; 33:358-71.
- Nilsson M, Norberg B, Hultdin J, Sandström H, Westman G, Lökk J. Medical intelligence in Sweden. Vitamin B12: oral compared with parenteral? *Postgrad Med J.* 2005;81:191-3.
- Graham ID, Jette N, Tetroe J, Robinson N, Milne S, Mitchell SL. Oral cobalamin remains medicine's best kept secret. *Arch Gerontol Geriatr.* 2007;44:49-59.
- Sharabi A, Cohen E, Sulkes J, Garty M. Replacement therapy for Vitamin B12 deficiency: comparison between the sublingual and oral route. *Br J Clin Pharmacol.* 2003;56:635-8.
- Carmel R. How I treat cobalamin (Vitamin B12) deficiency. *Blood.* 2008;112:2214-21.
- Stabler SP. Clinical practice. Vitamin B12 deficiency. *N Engl J Med.* 2013;368:149-60.
- Sezer RG, Akoğlu HA, Bozaykut A, Özdemir GN. Comparison of the efficacy of parenteral and oral treatment for nutritional Vitamin B12 deficiency in children. *Hematology.* 2018;23:653-7.
- Verma D, Chandra J, Kumar P, Shukla S, Sengupta S. Efficacy of oral methylcobalamin in treatment of Vitamin B12 deficiency anemia in children. *Pediatr Blood Cancer.* 2017;64:e26698.
- Andrés E, Kaltenbach G, Noel E, Noblet-Dick M, Perrin AE. Short-term oral cobalamin therapy for food-related cobalamin malabsorption. *Ann Pharmacother.* 2003;37:301-2.